On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
About this item
Full title
Author / Creator
Feldman, E J , Cortes, J , DeAngelo, D J , Holyoake, T , Simonsson, B , O'Brien, S G , Reiffers, J , Turner, A R , Roboz, G J , Lipton, J H , Maloisel, F , Colombat, P , Martinelli, G , Nielsen, J L , Petersdorf, S , Guilhot, F , Barker, J , Kirschmeier, P , Frank, E , Statkevich, P , Zhu, Y , Loechner, S and List, A
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Lonafarnib is an orally bio-available farnesyltransferase inhibitor that prevents farnesylation of specific target proteins including Ras. In a multicenter study, 67 patients with advanced myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) were treated with a continuous oral dose of 200–300 mg of lonafarnib and were evaluated...
Alternative Titles
Full title
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_DiVA_org_uu_124874
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_124874
Other Identifiers
ISSN
0887-6924,1476-5551
E-ISSN
1476-5551
DOI
10.1038/leu.2008.156
